Population pharmacokinetic/pharmacodynamic analysis of erythropoiesis kinetics
نویسندگان
چکیده
In USA more than 12.5% of all infants are born preterm. Approximately 75% of all perinatal deaths occur among these preterm infants. Preterm infants are frequently very low in birth weight (VLBW) and receive multiple red blood cell (RBC) transfusions. These transfusions pose increased risk of infections and other complications. Since erythropoietin (EPO) stimulates RBC production, EPO treatment of VLBW infants has received attention as a modality for reducing transfusions in this group. The overall hypothesis of this work is that treatment optimization of EPO of anemia in preterm infants requires a comprehensive knowledge of the behavior of RBC and the pharmacokinetic/pharmacodynamics (PK/PD) relationship between EPO and erythropoiesis. Under that overall hypothesis, the specific aims were: 1) To describe erythropoiesis dynamics in preterm infants, 2) To determine and explain the variability in the response to EPO in preterm infants, 3) To evaluate newborn sheep as an experimental model for erythropoiesis in preterm infants, 4) To test the hypothesis that RBC lifespan is shortened under acute hypoxic stress conditions, 5) To test the hypothesis that EPO receptor (EPOR) pool size increases under hypoxic stress conditions and the change in EPOR pool size can be predicted using EPO clearance measurements, 6) To describe the effect of EPOR pool size changes on erythropoiesis kinetics. A model that describes erythropoiesis dynamics in preterm infants as a function of the plasma EPO concentration is presented in Chapter 2. In Chapter 3, several covariates are tested for their ability to identify infants with good EPO responsiveness. The lamb is also tested as an animal model for the erythropoiesis in preterm infants (Chapter 4). In Chapters 5-7, the effect of hypoxic stress conditions on RBC survival was explored defining the relation between the efficacy of EPO and survival of RBC produced as a result of EPO administration. RBC lifespan measurement methods are reviewed in Chapter 5. In Chapter 6, a new methodology for the measurement of RBC lifespan under
منابع مشابه
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis
Peginesatide (OMONTYS®) is an erythropoiesis-stimulating agent that was indicated in the United States for the treatment of anemia due to chronic kidney disease in adult patients on dialysis prior to its recent marketing withdrawal by the manufacturer. The objective of this analysis was to develop a population pharmacokinetic and pharmacodynamic model to characterize the time-course of peginesa...
متن کاملPopulation pharmacokinetic/pharmacodynamic modeling of insulin kinetics
Approved: Thesis Supervisor Title and Department
متن کاملPopulation Pharmacokinetic - Pharmacodynamic Analysis of Anidulafungin in Adult Patients with 1 Fungal Infections
Population Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Adult Patients with 1 Fungal Infections 2 Ping Liu 3 4 Clinical Pharmacology, Specialty Care, Pfizer Inc, Groton, CT, USA 5 6 7 Running title: Population PK-PD analysis of anidulafungin 8
متن کاملPopulation Pharmacokinetic - Pharmacodynamic Analysis of Voriconazole and Anidulafungin in 1 Adult Patients with Invasive
Population Pharmacokinetic-Pharmacodynamic Analysis of Voriconazole and Anidulafungin in 1 Adult Patients with Invasive Aspergillosis 2 Ping Liu and Diane R. Mould 3 4 Clinical Pharmacology, Global Established Pharma Business, Pfizer Inc., Groton, CT, USA 5 Projections Research Inc., Phoenixville, PA, USA 6 7 8 Running title: Population PK-PD analysis of voriconazole and anidulafungin in IA pat...
متن کاملPharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.
The primary objectives of this analysis were to determine which pharmacokinetic model most accurately describes the elimination pathways for piperacillin in the presence of tazobactam through population pharmacokinetic modeling and to characterize its pharmacodynamic profile. Once the optimal pharmacokinetic model was identified, Monte Carlo simulation of 10,000 subjects with ADAPT II was perfo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2015